The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma

Cancer

Volumn 119, Issue 12, 2013, Pages 2350-2357

  Hall, William A ^a   Colbert, Lauren E ^a   Liu, Yuan ^b   Gillespie, Theresa ^a,c   Lipscomb, Joseph ^c,d   Hardy, Claire ^a   Kooby, David A ^a,c   Prabhu, Roshan S ^a   Kauh, John ^a   Landry, Jerome C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

adjuvant radiation dose in resected pancreatic adenocarcinoma; adjuvant radiotherapy; pancreatic adenocarcinoma; postoperative management in resected pancreatic adenocarcinoma; resected pancreatic adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; SURVIVAL PREDICTION; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; UNITED STATES;

EID: 84878590347     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28047     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991; 161: 120-124; discussion 124-125.
3. Piorkowski RJ, Blievernicht SW, Lawrence W Jr, et al. Pancreatic and periampullary carcinoma. Experience with 200 patients over a 12 year period. Am J Surg. 1982; 143: 189-193.
4. Nitecki SS, Sarr MG, Colby TV, van Heerden JA,. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995; 221: 59-66.
5. Gudjonsson B,. Cancer of the pancreas. 50 years of surgery. Cancer. 1987; 60: 2284-2303.
6. Trede M, Schwall G, Saeger HD,. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990; 211: 447-458.
7. Geer RJ, Brennan MF,. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165: 68-72; discussion 72-73.
8. Lim JE, Chien MW, Earle CC,. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237: 74-85.
9. Kalser MH, Ellenberg SS,. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120: 899-903.
10. [no authors listed] Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987; 59: 2006-2010.
11. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997; 225: 621-633; discussion 633-636.
12. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008; 26: 3511-3516.
13. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008; 26: 3503-3510.
14. Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010; 17: 981-990.
15. Hazard L, Tward JD, Szabo A, Shrieve DC,. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer. 2007; 110: 2191-2201.
16. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230: 776-782; discussion 782-784.
17. Neoptolemos JP, Dunn JA, Stocken DD, et al. European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358: 1576-1585.
18. Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200-1210.
19. Abrams RA, Lillemoe KD, Piantadosi S,. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 2001; 358: 1565-1566.
20. Koshy MC, Landry JC, Cavanaugh SX, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005; 61: 965-966.
21. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299: 1019-1026.
22. Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys. 1999; 44: 1039-1046.
23. Winchester DP, Stewart AK, Bura C, Jones RS,. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004; 85: 1-3.
24. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007; 246: 734-740.
25. Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012; 82: 809-816.